Nestle investing $145M in Aimmune

The Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) will invest $145 million in food allergy company Aimmune Therapeutics Inc. (NASDAQ:AIMT) through the purchase of 7.6 million shares at $19.20. The price is a 17% premium to Aimmune's $16.47 closing price on Thursday before the deal was announced. Nestle will have a 15% stake in Aimmune.

The companies also entered into a two-year partnership to develop and commercialize food allergy therapies. Aimmune will own IP resulting from the collaboration, and Nestle will have an exclusive, three-month negotiation period for any programs Aimmune elects to partner...